Peptides for sleep: DSIP vs epitalon vs pinealon, ranked by evidence

Among peptides for sleep, DSIP (delta sleep-inducing peptide, also called emideltide) has the most human sleep research. In a small double-blind crossover study of six volunteers, it raised sleep in the 130 minutes after an infusion by 59% compared with placebo (Schneider-Helmert 1981, Human RCT, n=6). Epitalon raised a melatonin marker in a small trial, but no sleep trial of it was found on PubMed (searched 2026-10-26). Pinealon has only lab data. None of the three is FDA-approved, and in its briefing for a July 2026 advisory meeting FDA called DSIP’s insomnia evidence “inconclusive and at best preliminary” (FDA briefing, emideltide).

Peptide	US FDA and compounding status	WADA (2026 List; 2027 List from 2027-01-01)
DSIP (emideltide)	Not approved; not a registered drug in any country FDA searched (FDA briefing). Nomination withdrawn from Category 2 (FDA). FDA staff advised against 503A listing; FDA’s advisory committee voted 6–7 against on 2026-07-24 (meeting page; count as reported by trade press). Advisory; no FDA rule yet	S0 covers substances with no approval by any health agency (USADA; our reading). The 2027 List names “peptides” in general under S0, prohibited at all times (USADA)
Epitalon	Not approved; nomination withdrawn from Category 2. FDA staff advised against 503A listing; the committee voted 7–4 in favor on 2026-07-24 (as reported by trade press). Advisory; no FDA rule yet	S0 applies in our reading, and the 2027 List names peptides in general under S0
Pinealon	Not approved; not on FDA’s Category 2 page and not reviewed by the committee (as of 2026-10-26)	S0 applies in our reading
Strongest evidence	DSIP: small Human RCTs in insomnia (n=6 to 16), mixed results. Epitalon: Human RCT on a melatonin marker (n=40), no sleep outcome. Pinealon: Lab	—
Human trials	No registered sleep trial of any of the three on ClinicalTrials.gov (searched 2026-10-26); the only epitalon record, NCT07888595, tests a skin serum	—
Last checked	2026-10-26	—

Peptides for sleep, ranked by evidence

This roundup orders the three peptides by the strongest evidence each has for sleep. No peptide in this group is an approved sleep drug, so the tiers run from investigational peptides with human sleep trials, to those with human data on a sleep-related marker, to lab-only findings. Figures from different studies are cross-trial comparisons: the people, settings and measures differ, so they cannot be ranked against each other directly.

Peptide	Best evidence	Key finding
DSIP (emideltide)	Human RCT, crossover (n=6); Human RCT (n=16)	Sleep +59% vs placebo after a daytime infusion (Schneider-Helmert 1981); no major benefit in insomnia (Bes 1992)
Epitalon	Human RCT, blinding not stated (n=40)	Melatonin metabolite up 1.7-fold; sleep not measured (FDA briefing)
Epitalon	Animal (rhesus monkeys)	Raised evening melatonin in old monkeys (Khavinson 2001)
Pinealon	Lab (cell cultures)	Raised serotonin expression in aging brain-cell cultures (Khavinson 2014)

Tier 1: DSIP, the most-studied sleep peptide

DSIP is a nine-amino-acid peptide first isolated in 1977 from rabbit brain venous blood (Kovalzon 2006). Its early human results are its main benefit claim, and they were encouraging. In six chronic insomniacs, a single infusion brought longer sleep with fewer interruptions and no daytime sedation (Schneider-Helmert 1981, Human, n=6). In 14 middle-aged insomniacs given DSIP on seven successive nights, the author reported better night sleep from the first dose and higher daytime alertness (Schneider-Helmert 1987, Human controlled study, n=14). FDA’s summary of that study gives the size of the change: time to fall asleep went from 58.4 minutes at baseline to 27.6 minutes after the last injection, and total sleep from 313 to 385 minutes (FDA briefing). FDA noted that the comparison was against baseline and an outside control group, not a parallel placebo group. In an open study, 6 of 7 patients with severe insomnia had normal sleep for 3 to 7 months after a series of 10 injections (Kaeser 1984, Human case series, n=7).

Independent groups did not reproduce the size of those results. A double-blind crossover study found that DSIP’s sleep gains over four nights did not differ significantly from placebo nights, and called them “of little clinical significance” (Monti 1987, Human RCT). In 16 chronic insomniacs, DSIP’s statistically significant gains in sleep efficiency and sleep latency were weak and may partly reflect a chance change in the placebo group, and subjective sleep quality did not change (Bes 1992, Human RCT, n=16). The biology is also unsettled: no DSIP gene or receptor has been isolated, and a 2006 review called the sleep-factor hypothesis “extremely poorly documented and still weak” (Kovalzon 2006). In a 2009 anesthesia trial, DSIP raised heart rate and made anesthesia lighter rather than deeper (Pomfrett 2009, Human RCT, n=24). FDA found data only for intravenous DSIP, and the newest sleep trial found on PubMed is from 1992 (searched 2026-10-26).

Tier 2: epitalon, melatonin findings without sleep outcomes

Epitalon (also spelled epithalon; amino acids Ala-Glu-Asp-Gly) is a synthetic peptide modeled on epithalamin, a pineal-gland extract (FDA briefing, epitalon). Its sleep interest rests on melatonin, a pineal hormone that plays a key role in the sleep-wake cycle, although FDA’s reviewers note that low melatonin levels have not been consistently linked to insomnia in older adults. The most promising result is in monkeys: epitalon significantly raised evening melatonin in old rhesus monkeys and normalized their cortisol rhythm (Khavinson 2001, Animal). In people, FDA’s reviewers describe a placebo-controlled study of women aged 40 to 50, mostly night-shift workers, in which 40 with low melatonin output received a sublingual epitalon spray or placebo for 20 days. Urinary 6-sulfatoxymelatonin, a melatonin breakdown product, rose 1.7-fold on epitalon (FDA briefing, epitalon; Human RCT, n=40), matching the rise the authors report for middle-aged people (Ivko 2020). FDA noted that the publication did not specify blinding and did not measure sleep.

The limits are just as plain. A lab study found that the same peptide had no effect on melatonin release from young or old rat pineal glands (Djeridane 2003, Lab). Human melatonin findings for epithalamin, the animal extract (Korkushko 2004, Human, epithalamin), are not data on synthetic epitalon, which FDA treats as a different substance. A 2026 review concluded that epitalon is “biologically active but clinically unproven”, with no adequately powered randomized trial (Jain 2026, narrative review). Our MOTS-c vs SS-31 vs NAD+ comparison covers other peptides marketed for aging.

Tier 3: pinealon, lab findings only

Pinealon is a three-amino-acid peptide (Glu-Asp-Arg) from the same Russian research program as epitalon. In cell cultures, it limited oxidative damage and cell death in nerve and blood cells (Khavinson 2011, Lab) and raised serotonin expression in aging brain-cortex cells (Khavinson 2014, Lab). No sleep study of pinealon was found on PubMed (searched 2026-10-26). The one human study found tested pinealon and a second peptide, vesugen, in 32 adults with chronic illness, measured biological-age markers rather than sleep, and reported pro-oxidant activity and lower blood stem-cell counts (Meshchaninov 2015, Human, n=32, design not stated).

DSIP vs epitalon for sleep: which has more evidence?

DSIP has more evidence for falling asleep and staying asleep, because it is the only one of the three tested directly on sleep in people, with sleep-lab recordings in small double-blind studies (Schneider-Helmert 1981). That evidence is old, small and split, and FDA judged it insufficient (FDA briefing, emideltide). Epitalon has more evidence for raising melatonin output in middle-aged people with low levels (Ivko 2020), but no study shows that this changes sleep. The two numbers measure different things and come from different trials, so they are not a head-to-head result. Pinealon has the least evidence of the three. FDA lists approved insomnia drugs with established efficacy, including Belsomra (suvorexant), Rozerem (ramelteon) and Ambien (zolpidem) (FDA briefing, emideltide). A clinician is the person to decide what fits a given sleep problem.

Can DSIP and epitalon be combined?

DSIP and epitalon are often discussed together online. No controlled human study of the combination was found on PubMed or ClinicalTrials.gov (searched 2026-10-26), and FDA found no human study of either peptide given under the skin (FDA briefing, epitalon). No data on how the two interact were found. Our guide to peptide stacks explains why combination claims usually rest on single-peptide data.

Safety and regulatory status

DSIP: in the human studies FDA reviewed, 209 people received intravenous DSIP for 1 to 15 days, and the insomnia studies reported no significant side effects (FDA briefing, emideltide). In a 1984 withdrawal study of 107 people, nine had minor transient effects such as sweating, headache, nausea and vertigo, and three had serious reactions, including two with low blood pressure at the first injection. FDA also noted that, in animal studies, DSIP’s sleep effects act through the body’s opioid system, that it found no study of its addiction potential, and that it identified no two-year cancer studies. FDA concluded that safety is “insufficiently characterized” for repeated use and that a nine-amino-acid peptide given under the skin may trigger an immune response.

Epitalon: FDA found no clinical studies assessing epitalon’s safety in humans and concluded there are “no clinical data to support the safety” of epitalon in people (FDA briefing, epitalon). It also raised immune-response concerns for injected use. Epitalon once held an FDA orphan-drug designation for retinitis pigmentosa, granted on 2010-09-02 and revoked on 2016-01-06.

Pinealon: no human safety data for sleep use were found; the one human study reported pro-oxidant activity and fewer blood stem cells (Meshchaninov 2015).

US and sport: FDA lists DSIP and epitalon among substances whose Category 2 nominations were withdrawn, and says it “lacks sufficient information to know whether the drug would cause harm” (FDA Category 2 page). At the July 2026 meeting, the advisory committee voted 7–4 for listing epitalon and 6–7 against DSIP, as reported by trade press; the votes are non-binding and FDA has made no rule (FDA meeting page). Our explainer on the compounding vote covers what it changes. For athletes, from 2027-01-01 the WADA List names peptides in general under S0, prohibited at all times (USADA). Anyone who suspects a side effect from DSIP, epitalon, pinealon or any other drug or product can report it to the FDA through MedWatch.

How long do effects take in studies?

For DSIP, sleep-promoting effects in insomniacs appeared in the second hour after an infusion, after a slight arousing effect in the first hour (Schneider-Helmert 1981). In the seven-night study, improvements started with the first dose, grew with repeated doses and lasted into the first night after treatment stopped (Schneider-Helmert 1987). For epitalon, the melatonin-marker rise was measured after a 20-day course (FDA briefing, epitalon). No study reports a timeline for pinealon and sleep.